About: http://data.cimple.eu/news-article/4a2baded6ac9d63b5a089985e3d06e19144af155f4f621d50d9f0456

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/4a2baded6ac9d63b5a089985e3d06e19144af155f4f621d50d9f0456 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pfizer CEO Albert Bourla on Thursday said he was against a US-backed proposal to waive patents on Covid-19 vaccines and that production should be ramped up in existing facilities instead. In an interview with AFP, Bourla said his company, which developed its vaccine with German firm BioNTech, was "not at all" in favour of the call from the United States to waive patent protections for coronavirus jabs. The widely praised move by the US announced on Wednesday is seen by proponents as a way to boost production in developing countries that so far have received far fewer jabs. But Bourla, reflecting the pharmaceutical industry's long held position, insisted patents are not the main roadblocks to more production and that building new plants would be counterproductive. "We should focus our efforts in what we can build right now, that is enough capacity to produce billions of doses," he said. "The problem is that there are no facilities in the world outside the ones that we can build ourselves, that can make mRNA vaccines," he said, referring to type of Covid vaccine developed by Pfizer and BioNTech. Bourla cautioned firmly against disrupting current operations "with politically motivated announcements." "They are empty promises," he added. Earlier, BioNTech pointed to issues ranging from the set up of manufacturing sites to the sourcing of raw materials, to the availability of qualified personnel that were holding up the process. The German government on Thursday also stressed the importance of keeping patent protections intact after the EU said it was open to looking into the idea. "The protection of intellectual property is a source of innovation and must remain so in the future," a government spokeswoman said. bur-jug/arp/dl
schema:headline	Pfizer CEO 'not at all' in favour of US patent waiver
schema:mentions	Intellectual property Developing country Agence France-Presse Pharmaceutical industry Patent Messenger RNA Chief executive officer European Union Pfizer Coronavirus disease Vaccine United States Coronavirus Coronavirus disease 2019 Air Raid Precautions in the United Kingdom
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-05-06 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	81 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software